$1.51
3.82%
Nasdaq, Jul 03, 09:23 pm CET
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Tiziana Life Sciences PLC Sponsored ADR Stock price

$1.51
+0.09 6.34% 1M
+0.78 106.85% 6M
+0.81 116.89% YTD
+0.69 83.03% 1Y
+0.80 112.68% 3Y
-1.06 41.23% 5Y
-0.14 8.36% 10Y
-0.14 8.36% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
-0.06 3.82%
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Key metrics

Basic
Market capitalization
$168.3m
Enterprise Value
$164.7m
Net debt
positive
Cash
$3.7m
Shares outstanding
111.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
42.8
Financial Health
Equity Ratio
34.9%
Return on Equity
-
ROCE
-401.9%
ROIC
-568.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-15.7m | -
EBIT
$-15.8m | $-47.9m
Net Income
$-11.9m | $-15.9m
Free Cash Flow
$-1.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.4% | -
EBIT
12.2%
Net Income
33.0% | -
Free Cash Flow
90.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
0.8%
Employees
9
Rev per Employee
-
Show more

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 5.23 5.23
36% 36%
-
-16 -16
12% 12%
-
- Depreciation and Amortization 0.12 0.12
20% 20%
-
EBIT (Operating Income) EBIT -16 -16
12% 12%
-
Net Profit -12 -12
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Neutral
Seeking Alpha
23 days ago
Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralumab in early-stage Alzheimer's Disease is set to begin in 2025, targeting microglial activation and neuroinflammation. The global Alzheimer's Disease market is expected to reach $23.8 billion by 2031.
Positive
Proactive Investors
24 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Weill Cornell marks the fifth site participating in the trial, joining Yale University,...
Neutral
GlobeNewsWire
24 days ago
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosi...
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Mr. Elrifi
Employees 9
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today